Nvidia Reportedly Invests $5 Billion in Safe Superintelligence
The chipmaker's strategic partnership with Ilya Sutskever's research lab couples new capital with access to Vera Rubin computing systems.
Archive
The chipmaker's strategic partnership with Ilya Sutskever's research lab couples new capital with access to Vera Rubin computing systems.
The molecular design startup reached a $3.8 billion valuation while expanding partnerships with major drugmakers.
The Palo Alto company is developing robotic locations that dispense prescriptions with remote pharmacist oversight and round-the-clock access.
The biotechnology company is advancing seven programs and plans to form focused affiliates as individual assets reach clinical milestones.
The biotechnology company plans to move nonviral treatments for Duchenne muscular dystrophy and polycystic kidney disease toward clinical testing.
The longevity biotechnology company plans to move its first liver program toward human testing while expanding its discovery platform.
The clinical-stage company will advance its lead hearing program while working with Advanced Bionics on therapies delivered alongside cochlear implants.
The brain-computer interface company is preparing its PRIMA vision-restoration system for commercialization while funding a broader clinical pipeline.
The Mission Bay startup is building laboratory systems that use living neurons for AI workloads, an ambitious alternative to conventional silicon.